Published in J Bone Miner Res on June 01, 2000
2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ (2002) 9.89
Vitamin D levels and response to biphosphonates in postmenopausal women receiving glucocorticoid therapy. Osteoporos Int (2014) 5.05
Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int (2007) 3.12
Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest (2002) 1.99
Osteoporosis in men. Endocr Rev (2008) 1.80
Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol (2006) 1.73
Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos Int (2005) 1.68
Tolerability and compliance with risedronate in clinical practice. Osteoporos Int (2003) 1.51
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res (2016) 1.50
Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial. Osteoporos Int (2007) 1.44
Skeletal lead release during bone resorption: effect of bisphosphonate treatment in a pilot study. Environ Health Perspect (2002) 1.44
Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice. Osteoporos Int (2012) 1.42
UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos (2017) 1.40
A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int (2012) 1.36
Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am (2012) 1.32
Management of osteoporosis in men: an update and case example. CMAJ (2007) 1.29
Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol (2013) 1.18
Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol (2010) 1.16
TZDs and Bone: A Review of the Recent Clinical Evidence. PPAR Res (2008) 1.13
Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol (2010) 1.07
Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int (2004) 1.07
Advances in glucocorticoid-induced osteoporosis. Curr Rheumatol Rep (2011) 1.06
Premenopausal women and low bone density. Can Fam Physician (2006) 1.05
Aging and bone loss: new insights for the clinician. Ther Adv Musculoskelet Dis (2012) 1.02
Vertebral morphometry: current methods and recent advances. Eur Radiol (2008) 0.99
Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int (2003) 0.99
Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int (2005) 0.99
Reduced serum concentrations of 25-hydroxy vitamin D in Egyptian patients with systemic lupus erythematosus: relation to disease activity. Med Sci Monit (2011) 0.96
Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int (2009) 0.94
Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study. Osteoporos Int (2014) 0.92
Risk factors for vertebral fracture in menopausal or postmenopausal Japanese women with rheumatoid arthritis: a cross-sectional and longitudinal study. J Bone Miner Metab (2006) 0.90
Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty. Osteoporos Int (2007) 0.90
Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease. J Bone Miner Metab (2006) 0.90
Ileum resection is the most predictive factor for osteoporosis in patients with Crohn's disease. Osteoporos Int (2006) 0.85
Targeted treatment in COPD: a multi-system approach for a multi-system disease. Int J Chron Obstruct Pulmon Dis (2009) 0.85
Progress in osteoporosis and fracture prevention: focus on postmenopausal women. Arthritis Res Ther (2009) 0.85
Increase in prophylaxis of glucocorticoid-induced osteoporosis by pharmacist feedback: a randomised controlled trial. Osteoporos Int (2013) 0.84
Incidence of vertebral deformities in 255 female rheumatoid arthritis patients measured by morphometric X-ray absorptiometry. Osteoporos Int (2004) 0.83
Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England. Osteoporos Int (2005) 0.82
Glucocorticoid-induced osteoporosis: treatment update and review. Ther Adv Musculoskelet Dis (2009) 0.82
Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. Osteoporos Int (2003) 0.82
Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies. Osteoporos Int (2003) 0.82
Glucocorticoid-induced osteoporosis. RMD Open (2015) 0.82
Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab (2014) 0.81
Effectiveness of alendronate and etidronate in the treatment of osteoporosis in men: a prospective observational study. Osteoporos Int (2005) 0.81
Medical treatment of vertebral osteoporosis. Eur Spine J (2003) 0.80
Glucocorticosteroid-induced spinal osteoporosis: scientific update on pathophysiology and treatment. Eur Spine J (2006) 0.80
Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid. Arthritis Res Ther (2010) 0.80
Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge. Postgrad Med J (2002) 0.80
Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science. Osteoporos Int (2008) 0.80
Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Osteoporos Int (2012) 0.79
Longitudinal practice patterns of prophylaxis of glucocorticoid-induced osteoporosis in patients with polymyalgia rheumatica. Rheumatol Int (2014) 0.79
Systematic review of trends in prophylaxis of corticosteroid-induced osteoporosis: the need for standard audit guidelines. Osteoporos Int (2008) 0.78
Advances in the management of corticosteroid-induced osteoporosis with bisphosphonates. Clin Rheumatol (2006) 0.78
Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures. Clin Rheumatol (2006) 0.78
Updates on mechanism of action and clinical efficacy of risedronate in osteoporosis. Clin Cases Miner Bone Metab (2014) 0.78
Zoledronic Acid for the treatment and prevention of primary and secondary osteoporosis. Ther Adv Musculoskelet Dis (2010) 0.78
Review of the safety and efficacy of risedronate for the treatment of male osteoporosis. Clin Interv Aging (2007) 0.78
Multidetector-row computed tomography is useful to evaluate the therapeutic effects of bisphosphonates in glucocorticoid-induced osteoporosis. J Bone Miner Metab (2013) 0.77
Comparison of the effect of vitamin K(2) and risedronate on trabecular bone in glucocorticoid-treated rats: a bone histomorphometry study. Yonsei Med J (2009) 0.77
Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis. Ther Clin Risk Manag (2010) 0.77
Prevention and treatment of corticosteroid-induced osteoporosis. Yonsei Med J (2005) 0.77
Steroids cause osteoporosis. Ann Rheum Dis (2002) 0.77
Comparative Efficacy of Bisphosphonates to Prevent Fracture in Men with Osteoporosis: A Systematic Review with Network Meta-Analyses. Rheumatol Ther (2016) 0.77
Medical treatment of osteoporotic vertebral fractures. Ther Adv Musculoskelet Dis (2011) 0.76
Management of glucocorticoid-induced osteoporosis: prevalence, and emerging treatment options. Drug Healthc Patient Saf (2010) 0.76
Mesenchymal precursor cells. Ann Rheum Dis (2002) 0.76
Treatment of glucocorticoid-induced osteoporsis. Ther Adv Musculoskelet Dis (2009) 0.76
Cosegregation of cardiovascular diseases and osteoporosis: instrumental diagnosis. Clin Cases Miner Bone Metab (2008) 0.75
An opportunity for improving osteoporosis treatment in home health care. Geriatr Orthop Surg Rehabil (2010) 0.75
Very high frequency of fragility fractures associated with high-dose glucocorticoids in postmenopausal women: A retrospective study. Bone Rep (2016) 0.75
Do the benefits of alendronate for premenopausal women on high-dose glucocorticoids outweigh the risks? Nat Clin Pract Rheumatol (2009) 0.75
A Novel Hybrid Compound LLP2A-Ale Both Prevented and Rescued the Osteoporotic Phenotype in a Mouse Model of Glucocorticoid-Induced Osteoporosis. Calcif Tissue Int (2016) 0.75
Outcomes of early and late immunomodulatory treatment in patients with HLA-B27-associated chronic uveitis. Graefes Arch Clin Exp Ophthalmol (2003) 0.75
Prescription for antiresorptive therapy in Mexican patients with rheumatoid arthritis: is it time to reevaluate the strategies for osteoporosis prevention? Rheumatol Int (2012) 0.75
Adverse bone effects of medications used to treat non-skeletal disorders. Osteoporos Int (2017) 0.75
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med (1995) 5.73
Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum (1988) 4.60
Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet (1997) 4.43
Controlled trial prednisolone in acute polyneuropathy. Lancet (1978) 3.71
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab (2005) 3.67
Alendronate for the treatment of osteoporosis in men. N Engl J Med (2000) 3.11
Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum (2003) 2.94
The impact of long-term warfarin therapy on quality of life. Evidence from a randomized trial. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. Arch Intern Med (1991) 2.92
Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int (2006) 2.79
Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study. Circulation (1990) 2.74
A prospective study of acute idiopathic neuropathy. II. Antecedent events. J Neurol Neurosurg Psychiatry (1988) 2.63
A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value. J Neurol Neurosurg Psychiatry (1988) 2.56
Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry (1997) 2.52
The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res (2003) 2.50
A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol (2000) 2.47
Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol (1998) 2.47
Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA (1997) 2.46
Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford) (2004) 2.37
The time course of a hypercalcaemic crisis in acute primary hyperparathyroidism. Lancet (1984) 2.21
Patient satisfaction after total knee arthroplasty: a comparison between subjective and objective outcome assessments. J Arthroplasty (2001) 2.16
Nosocomial multiply resistant Klebsiella pneumoniae: epidemiology of an outbreak of apparent index case origin. Antimicrob Agents Chemother (1979) 2.13
Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum (2001) 2.11
Epidemiological study of Guillain-Barré syndrome in south east England. J Neurol Neurosurg Psychiatry (1998) 2.07
The psychometric properties of clinical rating scales used in multiple sclerosis. Brain (1999) 2.06
The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler (1999) 2.02
Imaging in transient regional osteoporosis. Br J Rheumatol (1997) 2.01
Stroke prevention in nonvalvular atrial fibrillation. Ann Intern Med (1991) 2.01
Relapsing polychondritis. Three cases with a clinico-pathological study and literature review. Q J Med (1972) 1.87
The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Osteoporos Int (2009) 1.85
Overview of azathioprine treatment in multiple sclerosis. Lancet (1991) 1.83
The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology (1999) 1.82
Quantitative heel ultrasound in a population-based study in Italy and its relationship with fracture history: the ESOPO study. Osteoporos Int (2005) 1.80
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int (2008) 1.76
Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology (2001) 1.74
High prevalence of hypovitaminosis D in female type 2 diabetic population. Diabetes Care (2001) 1.74
Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA (2001) 1.72
Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med (2001) 1.69
Antibodies to gangliosides in Guillain-Barré syndrome: specificity and relationship to clinical features. Q J Med (1993) 1.67
Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital. Antimicrob Agents Chemother (1991) 1.67
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus (1995) 1.63
Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry (2000) 1.62
Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int (2000) 1.62
Anti-ganglioside GM1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection. Ann Neurol (1995) 1.60
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) (2000) 1.59
Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum (1998) 1.59
Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. Am J Med (1990) 1.57
Trigeminal sensory neuropathy. A study of 22 cases. Brain (1987) 1.56
Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med (2000) 1.55
Incidence and costs of hip fractures compared to acute myocardial infarction in the Italian population: a 4-year survey. Osteoporos Int (2006) 1.54
Prospective study of the usefulness of sural nerve biopsy. J Neurol Neurosurg Psychiatry (2000) 1.50
Intravertebral vacuum cleft: changes in content after supine positioning. Radiology (1993) 1.50
Guillain-Barré syndrome after treatment with streptokinase. BMJ (1992) 1.48
A case of fatal peri-partum cardiomyopathy. Br Heart J (1970) 1.46
Dissociation of parathyroid hormone bioactivity and immunoreactivity in pseudohypoparathyroidism type I. J Clin Endocrinol Metab (1981) 1.45
Bone loss in response to long-term glucocorticoid therapy. Bone Miner (1990) 1.44
Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab (1999) 1.43
Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet (1984) 1.43
Acute inflammatory polyneuropathy. Br J Hosp Med (1978) 1.42
Vasculitic neuropathy in association with chronic graft-versus-host disease. J Neurol Sci (1999) 1.41
Nosocomial febrile illnesses in patients on an internal medicine service. Arch Intern Med (1989) 1.41
Tolerability of risedronate in postmenopausal women intolerant of alendronate. Aging (Milano) (2001) 1.40
Clinical scales for multiple sclerosis. J Neurol Sci (1996) 1.39
Intravenous IgG in Guillain-Barré syndrome. BMJ (1996) 1.38
Chronic relapsing axonal neuropathy: a first case report. Ann Neurol (1995) 1.38
Bone mass evolution after renal transplantation. Kidney Int (2001) 1.38
Methotrexate-related pulmonary complications in rheumatoid arthritis. Ann Rheum Dis (1994) 1.37
Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors. Osteoporos Int (2003) 1.36
The effects of methotrexate on pregnancy, fertility and lactation. QJM (1999) 1.36
Prognosis in Guillain-Barré syndrome. Lancet (1985) 1.33
The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain (2001) 1.32
Regional distribution, developmental changes, and cellular localization of CNTF-mRNA and protein in the rat brain. J Cell Biol (1991) 1.30
The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum (2001) 1.30
Inter-laboratory validation of an ELISA for the determination of serum anti-ganglioside antibodies. Eur J Neurol (1999) 1.28
Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry (1999) 1.27
The course of patients with suspected myocardial infarction. The identification of low-risk patients for early transfer from intensive care. N Engl J Med (1980) 1.27
Change in bone mineral density in patients with rheumatoid arthritis during the first decade of the disease. Arthritis Rheum (2001) 1.26
Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis. Arthritis Rheum (2000) 1.25
Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporos Int (2012) 1.25
Plasma exchange for Guillain-Barré syndrome. Br Med J (Clin Res Ed) (1985) 1.24
Inhomogeneity of human vertebral cancellous bone: systematic density and structure patterns inside the vertebral body. Bone (2001) 1.24
The susceptibility of rat strains to experimental allergic encephalomyelitis. Immunology (1973) 1.23
Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res (2002) 1.22
Identification of the neuritogen for experimental allergic neuritis. Nature (1979) 1.21
Reliability of distance estimation by doctors and patients: cross sectional study. BMJ (1998) 1.21
Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev (2002) 1.20
Association between glycoconjugate antibodies and Campylobacter infection in patients with Guillain-Barré syndrome. J Neuroimmunol (1991) 1.19
Multiple mononeuropathy as the initial presentation of systemic lupus erythematosus--nerve biopsy and response to plasma exchange. J Neurol (1982) 1.19
Levels of circulating tumor necrosis factor alpha and interleukin-6 in patients with rheumatoid arthritis. Relationship to serum levels of hyaluronan and antigenic keratan sulfate. Arthritis Rheum (1993) 1.18
Ciliary neurotrophic factor. J Neurobiol (1994) 1.17
Lymphocyte subpopulations and suppressor cell activity in acute polyradiculoneuritis (Guillain-Barré syndrome). Clin Exp Immunol (1983) 1.17
An assessment of disability rating scales used in multiple sclerosis. Arch Neurol (1991) 1.16
Experimental allergic neuritis in the Lewis rat: characterization of the activity of peripheral myelin and its major basic protein,P2. Brain Res (1980) 1.14
The effect of low dosage glucocorticoids on bone mass in rheumatoid arthritis: a cross-sectional and a longitudinal study using single photon absorptiometry. Adv Exp Med Biol (1984) 1.14
Mixed or immune complex cryoglobulinaemia and neuropathy. J Neurol Neurosurg Psychiatry (1974) 1.13
[Articular amyloidosis, femoral neck fracture and chronic periodic hemodialysis]. Rev Rhum Mal Osteoartic (1985) 1.13
Radioimmunoassay of 1,25-dihydroxy vitamin D2: studies on the metabolism of vitamin D2 in man. Clin Endocrinol (Oxf) (1983) 1.13